Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 3, 2008, Pages 224-228

  Ibanez L ^a,b,c   Sabate M ^a,c   Ballarin E ^a,c   Puig, R ^c   Vidal, X ^a,b,c   Laporte, J R ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Fundacion Institut Catala de Farmacologia   (Spain)

Author keywords

Drug induced agranulocytosis; Filgrastim; Granulocyte colony stimulating factor; Neutropenia

Indexed keywords

ANTIBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SPAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; CHILD; CHILD, PRESCHOOL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 40949089008     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1542     Document Type: Article

References (15)

1. Medina PJ, George JN. Drug-associated blood dyscrasias. Adv Drug React Bull 2001; 210: 803-806.
2. Kaufman DW, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia. Oxford University Press: New York, 1991.
3. Ibáñez L, Vidal X, Ballarín E, Laporte J-R. Population-based drug-induced agranulocytosis. Arch Intern Med 2005; 165: 869-874.
4. Young NS. Agranulocytosis. JAMA 1994; 271: 935-938.
5. Andrès E, Kurtz J-E, Maloisel F. Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature. Clin Lab Haematol 2002; 24: 99-106.
6. Julià A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991; 79: 366-371.
7. Palmblad J, Papadaki HA, Eliopoulus G. Acute and chronic neutropenias. What is new? J Intern Med 2001; 250: 476-491.
8. Maloisel F, Andrès E, Kaltenbach G, Noel E, Komarianou A. Prognostic factors of hematologic recovery in non-chemotherapy drug-induced agranulocytosis. Haematologica 2003; 88: 470-471.
9. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354: 2034-2045.
10. Beauchesne MF, Shalansky SJ. Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy 1999; 19: 299-305.
11. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999; 9: 29-31.
12. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 2003; 12: 551-558.
13. Sprikkelman A, de Wolf JT, Vellenga E. The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia 1994; 8: 2031-2036.
14. Andrès E, Maloisel F, Kurtz JE, et al. Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med 2002; 13: 324-328.
15. McMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001; 357: 455-462.